Jiankui He

He Jiankui: The Man Who Edited Two Children

In November 2018, days before the Second International Summit on Human Genome Editing convened in Hong Kong, a little-known associate professor from Shenzhen released a set of videos announcing that twin girls had been born with edited genomes. He had disabled a gene called CCR5, he said, to make them resistant to HIV. He registered the clinical trial on 8 November 2018 — reportedly the day the twins were born, which is to say months after the experiment was already underway. Within a year he was in prison. The episode remains the single most consequential act of scientific misconduct of the CRISPR era, and its author was, by every measure his teachers used, exceptionally clever.

Rice Farms and Six Soccer Fields

He Jiankui was born in 1984 in Xinhua County, an impoverished corner of Hunan province, the son of rice farmers. As a schoolboy he assembled a rudimentary laboratory at home and fixed on physics. He took an undergraduate degree in modern physics at the University of Science and Technology of China in 2006, then went to Rice University in Houston — reportedly the only graduate school that admitted him.

At Rice he worked under the physicist Michael Deem on mathematical modelling and computer simulation of biological systems, and finished his doctorate in well under four years, with a thesis on the evolution of CRISPR. Deem's assessment at the time was unambiguous: a "very high-impact student" who would "be highly successful in his career." He ran the Rice Chinese Students and Scholars Association, four hundred members strong, and made no secret of enjoying himself. "I love to play soccer," he said. "Oh, my God, Rice has six soccer fields!"

A postdoctoral year at Stanford followed, in 2011, with the bioengineer Stephen Quake, working on CRISPR/Cas9.

The Fastest Man in Shenzhen

He returned to China in 2012 under Shenzhen's Peacock Plan and joined the new Southern University of Science and Technology as, at twenty-eight, its youngest associate professor. He founded Direct Genomics to build single-molecule DNA sequencers derived from Quake's technology, and later Vienomics Biotech for cancer genome sequencing. By 2017 Direct Genomics had drawn 200 million yuan — around thirty million dollars — from investors, plus another forty million in government subsidy. That same year he was named to China's Thousand Talents Plan, and state media promoted him enthusiastically.

He had, in other words, everything a young Chinese scientist was supposed to want. What he did not have was a single publication in the field he was about to detonate.

Everyone Told Him No

The most damning fact about the CRISPR-babies affair is that it was not a secret impulse. He spent two years telling senior Western scientists roughly what he intended, and being told, each time, not to.

In late 2016 he met Mark DeWitt of Berkeley's Innovative Genomics Institute for coffee, opening months of technical conversation about detecting off-target mutations; when he disclosed that he meant to establish pregnancies with edited embryos, DeWitt told him flatly there was no justification for such an experiment. In January 2017 Jennifer Doudna and the Stanford bioethicist William Hurlbut invited him to a workshop at Berkeley; his presentation on edited mouse, monkey and human embryos, Doudna recalled, "did not leave much of an impression," and colleagues found the work sloppy and the application unnecessary.

At Cold Spring Harbor in July 2017 he presented embryo data and — bizarrely — lectured his audience on the dangers of off-target edits and mosaicism. The computational biologist Max Haeussler was baffled: "Everyone in the room knew that it's out of the question to edit human embryos. Why mention that it's dangerous?"

In February 2018 he sat down with Stanford's Matthew Porteus, who was, in his own word, blindsided — and angry. Porteus told him the technology was not ready, that CCR5 carried no adequate medical justification, and that he would endanger the entire field. He came away convinced of something worse than recklessness. "He didn't even acknowledge what he was doing might be wrong," Porteus said. "I think he was looking for someone to tell him it was a great thing to do."

Hurlbut, who spent four- and five-hour sessions with him on science and ethics, put it with equal clarity: "I knew where he was heading. I tried to give him a sense of the practical and moral implications." The Harvard bioethicist Sheila Jasanoff noticed the "great smoothness" and, beneath it, that he "clearly did not have deep misgivings about plugging ahead."

His own justification leaned on stigma rather than infection: he had visited a Chinese village where HIV rates approached thirty percent, and spoke of people who struggled to find jobs, spouses, housing. In the submission to his hospital ethics committee, he promised something "more significant than the IVF technique which won the 2010 Nobel Prize." He mentioned Robert Edwards, the Nobel laureate who pioneered IVF, repeatedly. Those who dealt with him in 2018 came away with the same word: grandiose.

Suspension, Trial, Prison

On 29 November 2018 Chinese authorities suspended his research, describing his conduct as extremely abominable in nature. Investigators concluded he had forged ethical approval documents and raised funds specifically to evade oversight. SUSTech dismissed him. On 30 December 2019 he was convicted of illegal medical practice and sentenced to three years in prison and a fine of three million yuan; two collaborators received shorter sentences. A third edited child, later referred to as Amy, had also been born.

He was released in April 2022. He has since set up a laboratory in Beijing working on gene therapy for Duchenne muscular dystrophy. In February 2023 a Hong Kong work visa was granted and then revoked when false statements were found in the application. In September 2023 Wuchang University of Technology named him founding director of its Genetic Medicine Institute.

Why He Is Called a Genius

The word attaches to him mostly as a description of raw candlepower, and on that narrow ground the evidence is real. He came from a rice-farming county in Hunan, took a degree in modern physics at one of China's best universities, finished a biophysics doctorate at an American research university in under four years on a subject — CRISPR's evolutionary origins — that had barely become a field, and by twenty-eight was his university's youngest associate professor and the founder of a company that raised thirty million dollars. That is not luck. It is speed, range and formidable technical facility.

But the honest counter-case is close to total, and it matters more than the ability does. Nothing he did in 2018 was scientifically novel: CRISPR germline editing was well-established technique, and the field's restraint was ethical, not technical. He crossed a line others had chosen not to cross, which is transgression, not insight. His actual execution was judged sloppy by the specialists who saw it, the CCR5 target was judged medically unjustified by the field's leading practitioners, and he was warned, in detail, by the best people in the field, and proceeded anyway. He falsified approvals. He put three children into a permanent, unconsented biological experiment.

Genius, if the word is to keep any usefulness, describes a mind that sees further than its peers. He did not see further. He saw the same thing everyone else saw, and mistook the collective decision not to do it for a queue he could jump.

Legacy

His legacy is a hardening. The affair triggered a global tightening of rules on human germline editing and a blunt consensus that it must not proceed without oversight, safety data and genuine medical need. It became the field's standing cautionary tale — the name invoked whenever ambition threatens to outrun consent. And somewhere in China are three children who did not choose to be famous, and whose long-term health remains, by design of an experiment nobody sanctioned, unknown.